Erasca's Pan-RAS Molecule Either Validates Years of Losses Tomorrow or Resets the Clock

Erasca Inc. (ERAS) is scheduled to report first-quarter 2026 earnings on May 12, 2026, with the consensus estimate calling for a loss of $0.19 per share—a significant deterioration from the prior quarter's $0.10 loss. The central question for investors: can the clinical-stage biotech company demonstrate meaningful progress in its RAS/MAPK pathway-targeting pipeline to justify the widening losses, or will mounting cash burn and clinical setbacks trigger another sharp selloff? With the stock trading at $10.44 and down sharply from recent highs, this report will test whether the market's enthusiasm for ERAS-0015 and ERAS-4001 can withstand near-term financial pressure.

Part 1: Earnings Preview

Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, both advancing through Phase 1 trials.

Erasca is expected to report Q1 2026 results on May 12, 2026, with analysts forecasting a loss of $0.19 per share on no revenue. The company most recently reported a loss of $0.10 per share for Q4 2025, beating the $0.11 consensus estimate. Year-over-year, the expected Q1 loss of $0.19 represents a 72.73% deterioration compared to the $0.11 loss reported in Q1 2025, reflecting accelerated clinical spending as multiple programs advance.

Three key themes define this earnings story:

Clinical Momentum for ERAS-0015: Investors are watching for updates on the pan-RAS molecular glue following encouraging early data announced in January 2026, which showed confirmed partial responses across multiple tumor types at low doses with favorable safety profiles. The company has guided for Phase 1 monotherapy data in H1 2026—this earnings call could provide critical enrollment updates and timeline clarity for expansion cohorts planned for H2 2026.

Cash Runway and Burn Rate: With $341.8 million in cash as of year-end 2025 (before the January 2026 upsized financing that brought pro forma cash to $434 million), management's guidance that current resources will fund operations into H2 2028 will be scrutinized. Investors need visibility into quarterly burn rates as R&D expenses accelerate with two programs in clinical development and combination studies on the horizon.

ERAS-4001 Development Timeline: The pan-KRAS inhibitor is expected to deliver Phase 1 monotherapy data in H2 2026. Any updates on enrollment pace, early safety signals, or potential acceleration of expansion cohorts would be significant catalysts, especially given the competitive landscape in KRAS inhibition.

Analyst commentary ahead of the release emphasizes the importance of clinical execution. With 8 Strong Buy ratings and a mean price target of $20.30 (94% upside from current levels), the Street remains constructive on the long-term opportunity but is closely monitoring near-term cash consumption and data readout timing. The wide estimate range for Q1 (from a $0.09 loss to a $0.58 loss) reflects uncertainty around milestone payments and R&D spending variability.

Part 2: Historical Earnings Performance

Erasca has demonstrated a pattern of modest earnings performance relative to expectations over the past four quarters. The company reported a $0.11 loss in Q1 2025, beating the $0.12 estimate by 8.33%. Q2 2025 came in exactly at the $0.12 consensus, while Q3 2025 also matched estimates at $0.11. Most recently, Q4 2025 delivered a $0.10 loss versus the $0.11 estimate, representing a 9.09% beat.

The pattern reveals a company managing expenses relatively well against analyst models, with two beats and two in-line results across the trailing year. The sequential improvement from $0.11 to $0.10 in losses between Q3 and Q4 2025 suggests some operational efficiency, though the company remains deeply unprofitable as expected for a clinical-stage biotech. The upcoming Q1 2026 estimate of $0.19 represents a sharp sequential increase in losses, likely reflecting accelerated clinical trial costs as both ERAS-0015 and ERAS-4001 advance through dose escalation and toward expansion cohorts.

The consistency of small beats or in-line results indicates management has provided realistic guidance to the Street, avoiding major negative surprises. However, the widening loss trajectory—from $0.10 in Q4 2025 to an expected $0.19 in Q1 2026—underscores the cash-intensive nature of advancing multiple clinical programs simultaneously.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Erasca typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers and management commentary.

Historical price behavior around Erasca earnings reveals significant volatility, with an average absolute Day 0 move of 5.08% and Day +1 move of 4.60%. The most recent Q4 2025 report on March 12, 2026, triggered a 5.48% decline on Day 0 and a sharper 7.03% drop on Day +1, despite the company beating estimates—suggesting investors were disappointed by guidance or clinical updates rather than the headline number.

The eight-quarter history shows mixed directional outcomes but consistently wide trading ranges. Day 0 ranges have averaged 8.09%, while Day +1 ranges expand to 12.78%, indicating substantial intraday volatility as investors digest results and management commentary. Notable outliers include the November 2025 report, which saw a 12.29% Day 0 surge followed by a 4.15% Day +1 decline, and the May 2024 report, which produced a relatively muted Day 0 move but an 8.84% Day +1 selloff.

The pattern suggests investors should prepare for significant price swings regardless of whether the company beats or misses estimates. Clinical-stage biotech earnings often hinge more on pipeline updates, cash burn guidance, and trial timelines than on quarterly EPS figures, which explains why beats don't always translate to positive price action. The average Day +1 range of 12.78% implies substantial two-way risk heading into this report.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 9.12% for the May 15 expiration, which sits between the historical Day 0 average of 5.08% and the Day +1 average of 4.60%, but well below the average Day +1 trading range of 12.78%. This suggests options traders are anticipating meaningful volatility but may be underpricing the potential for extreme moves that have characterized past earnings reactions, particularly if clinical updates or cash guidance surprise investors.

Part 3: What Analysts Are Saying

Analyst sentiment on Erasca remains decidedly bullish despite recent price weakness. The consensus rating stands at 4.36 out of 5.0, reflecting strong conviction in the company's RAS-targeting franchise. The breakdown shows 8 Strong Buy ratings, 0 Moderate Buys, 2 Holds, 1 Moderate Sell, and 0 Strong Sells among the 11 analysts covering the stock.

The average price target of $20.30 implies 94% upside from the current price of $10.44, with a wide range spanning from a low of $9.00 to a high of $30.00. This dispersion reflects differing views on the probability of clinical success and the timeline to potential commercialization. The high target of $30.00 suggests at least one analyst sees transformative potential in the pipeline, while the $9.00 low target (below the current price) indicates skepticism about near-term value creation.

Sentiment has remained unchanged over the past month, with the rating count and average recommendation holding steady at 4.36. This stability suggests analysts are maintaining their positions heading into the Q1 report, likely awaiting the promised H1 2026 Phase 1 data for ERAS-0015 before making significant revisions. The concentration of Strong Buy ratings (8 of 11 analysts) indicates the Street views current levels as an attractive entry point for investors willing to accept clinical-stage risk, though the presence of a Moderate Sell rating serves as a reminder that execution risk remains substantial for a pre-revenue biotech.

Part 4: Technical Picture

Erasca's technical setup heading into earnings reflects significant recent weakness, with the Barchart Technical Opinion currently at 24% Buy—a sharp deterioration from 40% Buy one week ago and 100% Buy one month ago. This rapid decline in technical strength suggests momentum has turned decisively negative in the near term, with the stock breaking down from what was previously a strong bullish configuration.

Timeframe Analysis:

• Short-term (Hold): Neutral reading indicates near-term momentum has stalled after the recent selloff, with neither bulls nor bears in clear control
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate-term trend remains constructive despite recent weakness, potentially offering support
• Long-term (50% Buy): Moderate buy signal reflects the stock's longer-term uptrend remains intact, though under pressure

Trend Characteristics: The current trend is characterized as Soft in strength and Weakest in direction, indicating a fragile technical environment with deteriorating momentum heading into the earnings release.

The stock is trading at $10.44, positioned above its 5-day moving average of $10.37 and 10-day moving average of $10.17, but critically below its 20-day ($15.19), 50-day ($15.33), and 100-day ($12.00) moving averages. This configuration—above very short-term averages but below all intermediate-term averages—suggests a recent bounce within a broader downtrend. The stock remains above its 200-day moving average of $7.09, providing some longer-term technical support.

The technical picture heading into earnings is cautionary. The sharp breakdown below the 20-day and 50-day moving averages, combined with the collapse in the Barchart Technical Opinion from 100% Buy to 24% Buy in just one month, indicates significant technical damage. The $12.00 level (100-day moving average) represents overhead resistance, while the $10.17 level (10-day moving average) provides immediate support. With the stock trading in a narrow range near $10.44 after a steep decline from above $15, the setup suggests limited cushion for disappointment. Any negative surprises on clinical timelines, cash burn, or guidance could trigger a test of the $9.00 level (the low analyst price target), while positive catalysts would need to reclaim the $12.00 area to signal a meaningful technical reversal. The elevated options implied move of 9.12% and historical Day +1 range of 12.78% suggest traders should prepare for significant volatility regardless of direction.